The primary aim of this study was to identify effective prognostic biomarkers for breast cancer (BC), with a specific focus on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer, which represents a major subset of BC cases. This evidence concerns the gene NR4A1 and breast cancer.